Trial
NCT03644589
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
Merck Sharp & Dohme LLC
Condition
Estrogen Receptor Negative
Intervention
Pembrolizumab
Why stopped
No participants enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-26